We are live on ! Find out more
TTP

TITAN PHARMACEUTICAL INC
TTP

Delisted

TTP was delisted on the 24th of December, 2008.

1 hedge funds and large institutions have $4K invested in TITAN PHARMACEUTICAL INC in 2017 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 21 (-1)

97% less capital invested

Capital invested by funds: $124K → $4K (-$120K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
1
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
GS
Gagnon Securities
New York
-$116K
Name Holding Trade Value Shares
Change
Change in
Stake
VIA
1
Vantage Investment Advisors
Pennsylvania
$4K
GS
2
Gagnon Securities
New York
-$116K -35,092 Closed

TTP Hedge Fund Activity: Q2 2017 in Review

1 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in TITAN PHARMACEUTICAL INC (TTP) for Q2 2017, worth a combined $4K — down 97% from $124K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of TTP and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Gagnon Securities, exiting entirely with an estimated $116K sold.

  • 1 institutional investor held TITAN PHARMACEUTICAL INC (TTP) as of Q2 2017, down from 2 in Q1 2017.
  • Funds reported $4K of TITAN PHARMACEUTICAL INC stock for Q2 2017, down 97% quarter-over-quarter.
  • 0 funds opened new TITAN PHARMACEUTICAL INC positions in Q2 2017 and 1 closed out, a net change of -1 holder.
  • The largest TITAN PHARMACEUTICAL INC seller in Q2 2017 was Gagnon Securities, an estimated $116K sold.

Based on aggregated 13F filings for Q2 2017.